Related Experiment Video
Updated: Aug 3, 2025

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
HSP90 inhibition in the mouse spinal cord enhances opioid signaling by suppressing an AMPK-mediated negative feedback
Katherin A Gabriel1, John M Streicher1,2
1Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ, USA.
Abstract:
Opioids and other agonists of the μ-opioid receptor are effective at managing acute pain, but their chronic use can lead to tolerance that limits their efficacy. We previously reported that inhibiting the chaperone protein HSP90 in the spinal cords of mice promotes the antinociceptive effects of opioids in a manner that involved increased activation of the kinase ERK. Here, we found that the underlying mechanism involves the relief of a negative feedback loop mediated by the kinase AMPK. Intrathecal treatment of male and female mice with the HSP90 inhibitor 17-AAG decreased the abundance of the β1 subunit of AMPK in the spinal cord. The antinociceptive effects of 17-AAG with morphine were suppressed by intrathecal administration of AMPK activators and enhanced by an AMPK inhibitor. Opioid treatment increased the abundance of phosphorylated AMPK in the dorsal horn of the spinal cord, where it colocalized with a neuronal marker and the neuropeptide CGRP. Knocking down AMPK in CGRP-positive neurons enhanced the antinociceptive effects of morphine and demonstrated that AMPK mediated the signal transduction between HSP90 inhibition and ERK activation. These data suggest that AMPK mediates an opioid-induced negative feedback loop in CGRP neurons of the spinal cord and that this loop can be disabled by HSP90 inhibition to enhance the efficacy of opioids.
Insights
Inhibiting HSP90 enhances opioid pain relief by disrupting an AMPK-mediated feedback loop in spinal cord CGRP neurons. This strategy overcomes opioid tolerance and improves pain management.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Chronic opioid use leads to tolerance, limiting pain management efficacy.
- HSP90 inhibition previously enhanced opioid analgesia via ERK activation.
- The precise molecular mechanism remained unclear.
Purpose of the Study:
- To elucidate the mechanism by which HSP90 inhibition enhances opioid efficacy.
- To investigate the role of AMPK in opioid-induced tolerance and HSP90 inhibition effects.
Main Methods:
- Used intrathecal administration of HSP90 inhibitor (17-AAG) and morphine in mice.
- Assessed AMPK subunit abundance and phosphorylation in spinal cord tissue.
- Utilized AMPK activators and inhibitors to modulate pathway activity.
- Performed genetic knockdown of AMPK in CGRP-positive neurons.
Main Results:
- HSP90 inhibition reduced spinal cord AMPK β1 subunit abundance.
- AMPK activation suppressed 17-AAG's antinociceptive effects, while inhibition enhanced them.
- Opioid treatment increased phosphorylated AMPK in CGRP neurons.
- AMPK knockdown in CGRP neurons potentiated morphine's antinociceptive effects.
Conclusions:
- AMP-activated protein kinase (AMPK) mediates an opioid-induced negative feedback loop in spinal cord CGRP neurons.
- HSP90 inhibition disrupts this AMPK-mediated feedback loop, enhancing opioid efficacy.
- Targeting the HSP90-AMPK-ERK pathway offers a strategy to overcome opioid tolerance.
Related Concept Videos
Analgesia and Pain Management
Opioid Receptors: Overview
Opioid Analgesics: Synthetic and Semisynthetic Opioids
The JAK-STAT Signaling Pathway
Desensitization and Tachyphylaxis
GPCR Desensitization

